These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1215 related articles for article (PubMed ID: 12794024)

  • 1. Pentoxifyllin attenuates the systemic inflammatory response induced during isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan.
    Hohenberger P; Latz E; Kettelhack C; Rezaei AH; Schumann R; Schlag PM
    Ann Surg Oncol; 2003 Jun; 10(5):562-8. PubMed ID: 12794024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of systemic serum procalcitonin and cardiocirculatory reactions after isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan.
    Kettelhack C; Hohenberger P; Schulze G; Kilpert B; Schlag PM
    Crit Care Med; 2000 Apr; 28(4):1040-6. PubMed ID: 10809279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Procalcitonin as marker of systemic inflammatory reaction after isolated extremity perfusion].
    Kettelhack C; Hohenberger P; Furchtbar S; Schulze G; Schlag PM
    Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):399-402. PubMed ID: 14518284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
    Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
    Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [O2 utilization during hyperthermic extremity perfusion with rhTNF alpha and melphalan].
    Haier J; Hohenberger P; Beck K; Schlag PM
    Langenbecks Arch Chir; 1997; 382(3):128-33. PubMed ID: 9324610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of continuous leakage monitoring with radioactive iodine-131-labeled human serum albumin during hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan.
    van Ginkel RJ; Limburg PC; Piers DA; Koops HS; Hoekstra HJ
    Ann Surg Oncol; 2002 May; 9(4):355-63. PubMed ID: 11986187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan.
    Vrouenraets BC; Kroon BB; Ogilvie AC; van Geel AN; Nieweg OE; Swaak AJ; Eggermont AM
    Ann Surg Oncol; 1999 Jun; 6(4):405-12. PubMed ID: 10379864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic leakage and side effects of tumor necrosis factor alpha administered via isolated limb perfusion can be manipulated by flow rate adjustment.
    Sorkin P; Abu-Abid S; Lev D; Gutman M; Aderka D; Halpern P; Setton A; Kudlik N; Bar-On J; Rudich V
    Arch Surg; 1995 Oct; 130(10):1079-84. PubMed ID: 7575120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic and haemodynamic toxicity after isolated limb perfusion (ILP) with TNF-alpha.
    Laurenzi L; Natoli S; Di Filippo F; Calamaro A; Centulio F; Anzà M; Cavaliere F; Marcelli ME; Garinei R; Arcuri E
    J Exp Clin Cancer Res; 2004 Jun; 23(2):225-31. PubMed ID: 15354406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High plasma tumor necrosis factor (TNF)-alpha concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF-alpha, interferon-gamma, and melphalan.
    Zwaveling JH; Maring JK; Clarke FL; van Ginkel RJ; Limburg PC; Hoekstra HJ; Koops HS; Girbes AR
    Crit Care Med; 1996 May; 24(5):765-70. PubMed ID: 8706451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Assessment of regional and systemic toxicity of isolated hyperthermic extremity perfusion with tumor necrosis factor-alpha and melphalan].
    Hohenberger P; Haier J; Kettelhack C; Schulze G; Schlag PM
    Chirurg; 1997 Sep; 68(9):914-20. PubMed ID: 9410682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation.
    Gutman M; Inbar M; Lev-Shlush D; Abu-Abid S; Mozes M; Chaitchik S; Meller I; Klausner JM
    Cancer; 1997 Mar; 79(6):1129-37. PubMed ID: 9070490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of nitric oxide in recombinant tumor necrosis factor-alpha-induced circulatory shock: a study in patients treated for cancer with isolated limb perfusion.
    Zwaveling JH; Maring JK; Moshage H; van Ginkel RJ; Hoekstra HJ; Schraffordt Koops H; Donse IF; Girbes AR
    Crit Care Med; 1996 Nov; 24(11):1806-10. PubMed ID: 8917029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma.
    Hayes AJ; Neuhaus SJ; Clark MA; Thomas JM
    Ann Surg Oncol; 2007 Jan; 14(1):230-8. PubMed ID: 17066234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma.
    Grunhagen DJ; de Wilt JH; Graveland WJ; Verhoef C; van Geel AN; Eggermont AM
    Cancer; 2006 Apr; 106(8):1776-84. PubMed ID: 16541435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics.
    Bartlett DL; Ma G; Alexander HR; Libutti SK; Fraker DL
    Cancer; 1997 Dec; 80(11):2084-90. PubMed ID: 9392330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicity and morbidity of isolated limb perfusion.
    Vrouenraets BC; Klaase JM; Nieweg OE; Kroon BB
    Semin Surg Oncol; 1998; 14(3):224-31. PubMed ID: 9548605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma.
    Grunhagen DJ; de Wilt JH; Graveland WJ; van Geel AN; Eggermont AM
    Cancer; 2006 Jan; 106(1):156-62. PubMed ID: 16323177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolated limb perfusion: distinct tourniquet and tumor necrosis factor effects on the early hemodynamic response.
    Christoforidis D; Chassot PG; Mosimann F; Lienard D; Brunstein F; Bejko D; Lejeune FJ; Chiolero R
    Arch Surg; 2003 Jan; 138(1):17-25. PubMed ID: 12511144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan.
    Thom AK; Alexander HR; Andrich MP; Barker WC; Rosenberg SA; Fraker DL
    J Clin Oncol; 1995 Jan; 13(1):264-73. PubMed ID: 7799030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.